PedAM
Pediatric Disease Annotations & Medicines
| Disease | malabsorption syndrome |
| Phenotype | C0010674|cystic fibrosis |
| Sentences | 8 |
| PubMedID- 21197074 | Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic fibrosis (cf) and exocrine pancreatic insufficiency (pi). |
| PubMedID- 21459688 | Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. |
| PubMedID- 25782658 | Objectives: pancreatic enzyme replacement therapy (pert) is the proven therapy to substantially reduce fat malabsorption in patients with cystic fibrosis (cf). |
| PubMedID- 20179641 | Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid. |
| PubMedID- 22175008 | [224, 225] hypothesized that gln should be readily absorbed in cystic fibrosis children with malabsorption secondary to exocrine pancreatic insufficiency and maybe of potential benefit. |
| PubMedID- 23762044 | Factors influencing absorption include chemical form of copper, competitive antagonism by other metals (zinc, iron, selenium, cadmium), and malabsorption syndromes resulting from cystic fibrosis, celiac disease, gastrectomy, and jejunoileal bypass surgery. |
| PubMedID- 24743047 | Background: pancreatic insufficiency is common in patients with cystic fibrosis (cf) and leads to malabsorption of fat-soluble vitamins. |
| PubMedID- 26410283 | Pulmonary exacerbations and malabsorption in children with cystic fibrosis (cf) can lead to faltering growth and poor weight gain. |
Page: 1